Compare Cassava Sciences Inc (FLNA) vs Linde PLC (LIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Linde PLC — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while Linde PLC trades at $520.16 (market cap $237.72B). The key difference: Linde PLC is far larger — about 4473.5× Cassava Sciences Inc's market cap, and Linde PLC pays a 1.24% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | LIN | |
|---|---|---|
Market Cap | $53.14M | $237.72B |
Sector | Health | Basic Materials |
52-Week High | $4.64 | $546.64 |
52-Week Low | $1.09 | $389.38 |
Enterprise Value | -$33.43M | $260.07B |
Dividend Yield | — | 1.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Linde (LIN) trades at $522.54, down 0.29% on the day, with a bullish technical signal from moving averages and oversold RSI suggesting potential rebound. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $4.33 (beat), and robust profitability with a 20.44% net margin. Recent news highlights sustainability leadership and Q1 results showing 10% EPS growth.
Outlook remains positive given analyst consensus (85.7% buy ratings) and a $560 price target, though high valuation multiples (P/E 34.65) pose a risk if growth moderates. Key risks include rising debt-to-asset ratio (31.63% in 2025) and macroeconomic pressures on industrial demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
